Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo

@article{Chen2015ChemotherapeuticEO,
  title={Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo},
  author={Thomas C Chen and Hee-yeon Cho and Weijun Wang and Stephanie J. Wetzel and Anupam Kumar Singh and Jenny Nguyen and Florence M. Hofman and Axel H Sch{\"o}nthal},
  journal={Journal of Biomedical Science},
  year={2015},
  volume={22}
}
BackgroundMany patients with nasopharyngeal carcinoma (NPC) face poor prognosis. Due to its hidden anatomical location, the tumor is usually diagnosed quite late, and despite initially successful treatment with radiation and cisplatin, many patients will relapse and succumb to the disease. New treatment options are urgently needed. We have performed preclinical studies to evaluate the potential NPC therapeutic activity of a newly developed analog of temozolomide (TMZ), an alkylating agent that… Expand
NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo
TLDR
In vivo and in vitro results showed that NEO412 effectively killed melanoma cells, including TMZ-resistant and BRAF mutant ones, through DNA alkylation and subsequent apoptosis, and presented NEO412 as a potentially promising new treatment for cutaneous melanoma, in particular MIS, deserving of further study. Expand
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
TLDR
The aim of this review is to summarize the resistance mechanisms of TMZ and the current advances to improve its clinical use, including the use of nanomaterial delivery systems and the association with other chemotherapy agents. Expand
Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro
TLDR
It was established that fascaplysin at 0.5 µM has a strong cytotoxic effect, which is subsequently replaced by tumor cell death via apoptosis as the length of drug exposure time is increased, and the efficiency of fascap Elysin was observed to significantly exceed that of temozolomide. Expand
Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice
TLDR
NEO212 preferentially concentrates in brain tumor tissue over normal brain tissue, and compared to TMZ has a higher brain:plasma ratio, altogether revealing favorable features to encourage its further development as a brain-targeted therapeutic. Expand
NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
TLDR
In an in vivo orthotopic glioma model, NEO212 decreases tumor progression by reducing invasion of GSCs, thereby increasing survival time of mice, and indicates that NEO212, in addition to cytotoxicity, can effectively reduce migration and invasion in G SCs, thus exhibiting significant clinical value in the reduction of invasion and malignant gliomas progression. Expand
Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development
TLDR
POH is the only intranasally delivered compound in the field of cancer therapy (outside of cancer pain) that has advanced to active clinical trials and, when switched toIntranasal delivery, POH yielded highly promising activity in recurrent glioma patients and was well tolerated. Expand
Carboxamide derivatives induce apoptosis in the U251 glioma cell line.
TLDR
It is demonstrated that the carboxamide derivatives displayed antitumor activity against glioma in vitro, which may have been mediated via the induction of oxidative damage and apoptosis. Expand
Computer-aided design of temozolomide derivatives based on alkylglycerone phosphate synthase structure with isothiocyanate and their pharmacokinetic/toxicity prediction and anti-tumor activity in vitro
TLDR
The molecular biological differences between tumor and normal cells are utilized to design TMZ derivatives with improved selectivity and targeting using computer-aided drug design (CADD), suggesting their potential as anti-cancer drugs with adequate AGPS targeting, ADME/toxicity and anti-tumor activity. Expand
M3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites Carcinoma
TLDR
Development of new biotechnologies for restriction of tumor growth using in vitro reprogrammed M3 macrophages is very promising. Expand
Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma
TLDR
Findings suggest that promising biotechnologies for restriction of tumor growth could be developed based on the in vitro macrophage reprogramming in Ehrlich ascites carcinoma. Expand
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo
TLDR
In an intracranial mouse tumor model with triple-negative breast cancer, T-P revealed considerably greater therapeutic efficacy than TMZ, where a single cycle of treatment extended median survival benefit from 6 days to 28 days, and seemed to be well tolerated by the animals. Expand
Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
TLDR
The data show that POH is an effective anti-glioma cytotoxic agent for TMZ-resistant gliomas when administered intranasally and impeded survival pathways, such as mTOR and Ras. Expand
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
TLDR
Perillyl alcohol is well tolerated and regression of tumor size in some patients is suggestive of antitumor activity, and POH intranasal delivery is discussed as a potential adjuvant therapeutic strategy for patients with malignant gliomas. Expand
Temozolomide: mechanisms of action, repair and resistance.
TLDR
Several small molecule inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1), a critical BER protein are yielding promising results clinically, both in combination with TMZ and as single agent chemotherapy in patients whose tumours possess homologous recombination DNA repair defects. Expand
Novel therapy for nasopharyngeal carcinoma--where are we.
TLDR
The scientific basis and latest published results of the relevant clinical trials are highlighted, demonstrating the ongoing battle against NPC is indeed one of the most fascinating successes in head and neck oncology. Expand
Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.
TLDR
It is concluded that CCRT as a treatment paradigm is also applicable to patients in Southeast Asia and should be standard of practice in locally advanced disease. Expand
O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.
TLDR
Observations suggest a role for MGMT in directing adjuvant therapy of GBM and other gliomas, and approaches that may improve the utility of MGMT methylation status in planning optimal therapies tailored to individual patients are considered. Expand
Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma
TLDR
Intranasal administration of POH increased the overall survival of patients with recurrent GBM in comparison with historical untreated controls, but especially patients with secondary GBM and primary GBM with tumor localized in deep regions of the brain. Expand
Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.
TLDR
The vicissitudes of POH's evaluation as an anticancer agent, and its most recent success in therapy of patients with malignant brain tumors are presented. Expand
Characterization of seven newly established nasopharyngeal carcinoma cell lines.
  • C. Lin, W. Chan, +5 authors C. Wang
  • Biology, Medicine
  • Laboratory investigation; a journal of technical methods and pathology
  • 1993
TLDR
The newly established seven NPC cell lines have been well characterized, and all showed overexpression of c-myc oncogene, and its protein product was abnormal in certain interphase cells of each cell line. Expand
...
1
2
3
4
...